---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-069706"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2025-04-01T23:59:59+00:00"
generated_at: "2026-05-24T00:43:10.877981+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TuHURA reports FY2024 R&D $13.3M, cash through late Q4 2025; Phase 3 trial to start Q2

## Summary
- Full-year 2024 R&D expense $13.3M (up from $9.4M); G&A $4.3M (vs $4.1M prior year).
- Raised $36M in 2024; cash expected to fund operations through late Q4 2025.
- Phase 3 IFx-2.0 trial for MCC under SPA with FDA; enrollment targeted Q2 2025 (partial clinical hold on CMC).
- Acquisition of Kineta's VISTA antibody KVA12123 targeted to close Q2 2025.
- 2025 milestones include Phase 2 VISTA trial in AML; novel bi-specific ADC platform advancing.

## SEC filing metadata
- accession: 0001193125-25-069706
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2025-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000119312525069706/0001193125-25-069706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000119312525069706/d888264d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-069706
- JSON: https://secwatch.observer/filing/0001193125-25-069706.json
- Plain text: https://secwatch.observer/filing/0001193125-25-069706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.